GlassScriptPhysician profile
Debra B Lebo
NPI 1063470839
$12,156.34
in general payments reported to CMS, 2019-2025
39 companies · $2,892 in 2025
The $2,892 reported for 2025 was more than what 75% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $657 · 2021: $1,307 · 2022: $1,531 · 2023: $2,112 · 2024: $2,347 · 2025: $2,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,318 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,317.80 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,667.64 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,901.37 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,676.06 | 2019-2025 | Nucala |
| Optinose US, INC. | $1,030.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $669.90 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Alk-Abello, INC | $528.47 | 2019-2025 | Odactra, Grastek, Ragwitek |
| Genentech USA, INC. | $458.09 | 2019-2025 | Xolair |
| Grifols USA, LLC | $271.63 | 2020-2025 | Xembify |
| Hikma Pharmaceuticals USA | $265.81 | 2022-2025 | Ryaltris |
| Blueprint Medicines Corporation | $230.04 | 2023-2024 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $226.74 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $196.66 | 2023 | |
| Galderma Laboratories, L.P. | $195.11 | 2025 | Nemluvio |
| Ars Pharmaceuticals Operations, INC. | $191.37 | 2025 | Neffy |
| Lilly USA, LLC | $183.09 | 2024-2025 | Ebglyss |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $177.27 | 2019-2023 | Clarifix Cryotherapy Device, Xerogel Nasal/Epistaxis 2 Pack, Xpress Ent Dilation System |
| Inspire Medical Systems, INC. | $139.81 | 2023-2025 | Inspire |
| Incyte Corporation | $127.13 | 2021 | |
| Pfizer INC. | $110.74 | 2021-2025 | |
| Leo Pharma INC. | $103.10 | 2022-2025 | Anzupgo |
| Takeda Pharmaceuticals U.S.A., INC. | $97.21 | 2020-2022 | |
| Amgen INC. | $91.15 | 2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $79.87 | 2021 | |
| Aimmune Therapeutics, INC. | $69.30 | 2020-2022 | |
| Shire North American Group INC | $51.99 | 2019 | |
| Paratek Pharmaceuticals, INC. | $43.58 | 2025 | Xhance |
| Arcutis Biotherapeutics, INC. | $42.54 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $40.56 | 2019-2020 | |
| Octapharma USA, INC. | $40.46 | 2021-2024 | Cutaquig |
| Phadia US INC. | $39.05 | 2023-2024 | Immunocap |
| Acclarent, INC | $37.31 | 2020 | |
| Integra Lifesciences Corporation | $32.90 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Phathom Pharmaceuticals, INC. | $26.79 | 2024 | Voquezna |
| Aytu Biopharma, INC. | $21.77 | 2020 | |
| Photonicare INC | $21.57 | 2024 | Otosight Middle Ear Scope |
| Circassia INC. | $20.49 | 2019 | |
| Medtronic, INC. | $19.00 | 2024 | Propel |
| Csl Behring | $17.18 | 2019 | |
| Smith+Nephew, INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Lebo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.